<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zavaglio F</submitter><funding>Ministero della Salute</funding><funding>Fondazione Cariplo</funding><pagination>2261</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8621286</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>13(11)</volume><pubmed_abstract>The development and persistence of SARS-CoV-2-specific immune response in immunocompetent (IC) and immunocompromised patients is crucial for long-term protection. Immune response to SARS-CoV-2 infection was analysed in 57 IC and 15 solid organ transplanted (TX) patients. Antibody responses were determined by ELISA and neutralization assay. T-cell response was determined by stimulation with peptide pools of the Spike, Envelope, Membrane, and Nucleocapsid proteins with a 20-h Activation Induced Marker (AIM) and 7-day lymphoproliferative assays. Antibody response was detected at similar levels in IC and TX patients. Anti-Spike IgG, IgA and neutralizing antibodies persisted for at least one year, while anti-Nucleocapsid IgG declined earlier. Patients with pneumonia developed higher antibody le</pubmed_abstract><journal>Viruses</journal><pubmed_title>Robust and Persistent B- and T-Cell Responses after COVID-19 in Immunocompetent and Solid Organ Transplant Recipient Patients.</pubmed_title><pmcid>PMC8621286</pmcid><funding_grant_id>CoVIM, no. 2020-1374</funding_grant_id><funding_grant_id>BIAS no. 2020-12371760</funding_grant_id><pubmed_authors>Sammartino JC</pubmed_authors><pubmed_authors>Seminari E</pubmed_authors><pubmed_authors>Rizzi M</pubmed_authors><pubmed_authors>Morosini M</pubmed_authors><pubmed_authors>Mallela VR</pubmed_authors><pubmed_authors>Minisini R</pubmed_authors><pubmed_authors>Baldanti F</pubmed_authors><pubmed_authors>Cattadori B</pubmed_authors><pubmed_authors>Zavaglio F</pubmed_authors><pubmed_authors>Frangipane V</pubmed_authors><pubmed_authors>Sainaghi PP</pubmed_authors><pubmed_authors>Ferrari A</pubmed_authors><pubmed_authors>Rampino T</pubmed_authors><pubmed_authors>Di Matteo A</pubmed_authors><pubmed_authors>Tonello S</pubmed_authors><pubmed_authors>Gregorini M</pubmed_authors><pubmed_authors>Gabanti E</pubmed_authors><pubmed_authors>Zelini P</pubmed_authors><pubmed_authors>Meloni F</pubmed_authors><pubmed_authors>Pellegrini C</pubmed_authors><pubmed_authors>Asti A</pubmed_authors><pubmed_authors>Lilleri D</pubmed_authors></additional><is_claimable>false</is_claimable><name>Robust and Persistent B- and T-Cell Responses after COVID-19 in Immunocompetent and Solid Organ Transplant Recipient Patients.</name><description>The development and persistence of SARS-CoV-2-specific immune response in immunocompetent (IC) and immunocompromised patients is crucial for long-term protection. Immune response to SARS-CoV-2 infection was analysed in 57 IC and 15 solid organ transplanted (TX) patients. Antibody responses were determined by ELISA and neutralization assay. T-cell response was determined by stimulation with peptide pools of the Spike, Envelope, Membrane, and Nucleocapsid proteins with a 20-h Activation Induced Marker (AIM) and 7-day lymphoproliferative assays. Antibody response was detected at similar levels in IC and TX patients. Anti-Spike IgG, IgA and neutralizing antibodies persisted for at least one year, while anti-Nucleocapsid IgG declined earlier. Patients with pneumonia developed higher antibody le</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Nov</publication><modification>2025-05-31T23:33:23.446Z</modification><creation>2025-05-31T23:33:23.446Z</creation></dates><accession>S-EPMC8621286</accession><cross_references><pubmed>34835067</pubmed><doi>10.3390/v13112261</doi></cross_references></HashMap>